Accession Number:



Targeting Prostate Cancer with Multifunctional Nanoparticles

Descriptive Note:

Technical Report,30 Sep 2014,29 Sep 2015

Corporate Author:

Yale University New Haven United States

Personal Author(s):

Report Date:


Pagination or Media Count:



Prostate cancer cells were transfected with claudin siRNA duplexes using Lipofectamine RNAiMAX Invitrogen as well as the appropriate controls including vehicle, non-targeting siRNA siSC5 negative control and glyceraldehyde-3-phosphate dehydrogenase GAPD positive control. A time course and concentration curve was completed to determine the maximum down-regulation of claudin-3 and claudin-4 expression. In addition, cytotoxicity assays were performed to determine the number of viable prostate cancer cells upon claudin-3 siRNA or claudin-4 siRNA treatment. We were able to get great knockdown, which translated into a decrease in the number of viable prostate cancer cells by testing each target with 4 independent siRNAs for claudin-3 and claudin-4. In looking at our claudin-4 siRNA data, we treated prostate cancer cells in vitro for 72 hours, at concentrations of 25, 50 and 100 nM Fig 2, top. As can be seen from our data, there was approximately a 60 decrease in cell viability upon treatment with claudin-4 siRNA. In addition, our immunohistochemical data demonstrate that claudin-3 and claudin-4 are expressed in subsets of aggressive prostate cancer. Finally, we produced our first two batches of nanoparticles during year 1 and we were able to show that these nanoparticles bind to prostate cancer cells.

Subject Categories:

Distribution Statement: